Recombinase-based conditional and reversible gene regulation via XTR alleles

Nature Communications

Volumn 6, Issue , 2015, Pages

  Robles Oteiza, Camila ^a   Taylor, Sarah ^b   Yates, Travis ^a   Cicchini, Michelle ^a   Lauderback, Brian ^a   Cashman, Christopher R ^b   Burds, Aurora A ^b   Winslow, Monte M ^c   Jacks, Tyler ^b,d   Feldser, David M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; PROTEIN P53; RECOMBINASE; RETINOBLASTOMA PROTEIN; SYNTHETIC DNA; TAMOXIFEN; INTEGRASE;

ALLELE; CANCER; ENZYME ACTIVITY; GENE EXPRESSION; METABOLISM; PHYSIOLOGY; RODENT;

ALLELE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER MODEL; CELL LINE; CONTROLLED STUDY; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION SYSTEM; GENE FUNCTION; GENE INACTIVATION; GENE SWITCHING; GENE TARGETING; GERM LINE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOXP SITE; LUNG ADENOCARCINOMA; LUNG SARCOMA; MOUSE; NEOPLASM; NONHUMAN; REPORTER GENE; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; WILD TYPE; XTR SYSTEM; ANIMAL; DISEASE MODEL; ELECTROPORATION; EPITHELIUM CELL; EXPERIMENTAL NEOPLASM; FIBROBLAST; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; GERMLINE MUTATION; MAMMALIAN EMBRYO; METABOLISM; POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ALLELES; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ELECTROPORATION; EMBRYO, MAMMALIAN; EPITHELIAL CELLS; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, P53; GENES, REPORTER; GENES, RETINOBLASTOMA; GENES, SYNTHETIC; GERM-LINE MUTATION; INTEGRASES; MICE; NEOPLASMS, EXPERIMENTAL; POLYMERASE CHAIN REACTION;

EID: 84946606374     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9783     Document Type: Article

References (53)

1. Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665 (2007).
2. Feldser, D. M. et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468, 572-575 (2010).
3. Martins, C. P., Brown-Swigart, L. & Evan, G. I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323-1334 (2006).
4. Junttila, M. R. et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468, 567-571 (2010).
5. Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660 (2007).
6. Miething, C. et al. PTEN action in leukaemia dictated by the tissue microenvironment. Nature 510, 402-406 (2014).
7. Schnutgen, F. et al. A directional strategy for monitoring Cre-mediated recombination at the cellular level in the mouse. Nat. Biotechnol. 21, 562-565 (2003).
8. Schnutgen, F. et al. Genomewide production of multipurpose alleles for the functional analysis of the mouse genome. Proc. Natl Acad. Sci. USA 102, 7221-7226 (2005).
9. Stern, P. et al. A system for Cre-regulated RNA interference in vivo. Proc. Natl Acad. Sci. USA 105, 13895-13900 (2008).
10. Economides, A. N. et al. Conditionals by inversion provide a universal method for the generation of conditional alleles. Proc. Natl Acad. Sci. USA 110, E3179-E3188 (2013).
11. Carette, J. E. et al. Haploid genetic screens in human cells identify host factors used by pathogens. Science 326, 1231-1235 (2009).
12. Carette, J. E. et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477, 340-343 (2011).
13. Lee, C. C., Carette, J. E., Brummelkamp, T. R. & Ploegh, H. L. A reporter screen in a human haploid cell line identifies CYLD as a constitutive inhibitor of NF-kappaB. PLoS ONE 8, e70339. doi:10.1371/journal.pone.0070339.
14. Jae, L. T. et al. Deciphering the glycosylome of dystroglycanopathies using haploid screens for lassa virus entry. Science 340, 479-483 (2013).
15. Reiling, J. H. et al. A haploid genetic screen identifies the major facilitator domain containing 2A (MFSD2A) transporter as a key mediator in the response to tunicamycin. Proc. Natl Acad. Sci. USA 108, 11756-11765 (2011).
16. Reiling, J. H. et al. A CREB3-ARF4 signalling pathway mediates the response to Golgi stress and susceptibility to pathogens. Nat. Cell Biol. 15, 1473-1485 (2013).
17. Chiou, S. H. et al. A conditional system to specifically link disruption of protein-coding function with reporter expression in mice. Cell Rep. 7, 2078-2086 (2014).
18. Sherr, C. J. & DePinho, R. A. Cellular senescence: mitotic clock or culture shock? Cell 102, 407-410 (2000).
19. Christophorou, M. A. et al. Temporal dissection of p53 function in vitro and in vivo. Nat. Genet. 37, 718-726 (2005).
20. Tallquist, M. D. & Soriano, P. Epiblast-restricted Cre expression in MORE mice: a tool to distinguish embryonic vs. extra-embryonic gene function. Genesis 26, 113-115 (2000).
21. Jacks, T. et al. Effects of an Rb mutation in the mouse. Nature 359, 295-300 (1992).
22. Lee, E. Y. et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359, 288-294 (1992).
23. Adams, J. M. & Cory, S. Myc oncogene activation in B and T lymphoid tumours. Proc. R. Soc. Lond. B. Biol. Sci. 226, 59-72 (1985).
24. Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R. & Lowe, S. W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13, 2670-2677 (1999).
25. Schmitt, C. A. et al. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1, 289-298 (2002).
26. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243-3248 (2001).
27. Tuveson, D. A. et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5, 375-387 (2004).
28. Jackson, E. L. et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65, 10280-10288 (2005).
29. Kirsch, D. G. et al. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat. Med. 13, 992-997 (2007).
30. Lao, Z., Raju, G. P., Bai, C. B. & Joyner, A. L. MASTR: a technique for mosaic mutant analysis with spatial and temporal control of recombination using conditional floxed alleles in mice. Cell Rep. 2, 386-396 (2012).
31. Premsrirut, P. K. et al. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 145, 145-158 (2011).
32. Johnson, L. et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410, 1111-1116 (2001).
33. Dickins, R. A. et al. Tissue-specific and reversible RNA interference in transgenic mice. Nat. Genet. 39, 914-921 (2007).
34. Dow, L. E. et al. Apc restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer. Cell 161, 1539-1552 (2015).
35. Dow, L. E. et al. A pipeline for the generation of shRNA transgenic mice. Nat. Protoc. 7, 374-393 (2012).
36. Fellmann, C. et al. Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol. Cell 41, 733-746 (2011).
37. Dickins, R. A. et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat. Genet. 37, 1289-1295 (2005).
38. Hemann, M. T. et al. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat. Genet. 33, 396-400 (2003).
39. Kaelin, Jr. W. G. Molecular biology. Use and abuse of RNAi to study mammalian gene function. Science 337, 421-422 (2012).
40. Jackson, A. L. et al. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 12, 1179-1187 (2006).
41. Echeverri, C. J. et al. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat. Methods 3, 777-779 (2006).
42. Grimm, D. et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-541 (2006).
43. Fisher, G. H. et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15, 3249-3262 (2001).
44. Politi, K. et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 20, 1496-1510 (2006).
45. Ji, H. et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9, 485-495 (2006).
46. Moody, S. E. et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2, 451-461 (2002).
47. Farley, F. W., Soriano, P., Steffen, L. S. & Dymecki, S. M. Widespread recombinase expression using FLPeR (flipper) mice. Genesis 28, 106-110 (2000).
48. Yang, H. et al. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell 154, 1370-1379 (2013).
49. Yang, H., Wang, H. & Jaenisch, R. Generating genetically modified mice using CRISPR/Cas-mediated genome engineering. Nat. Protoc. 9, 1956-1968 (2014).
50. Young, N. P. & Jacks, T. Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. Proc. Natl Acad. Sci. USA 107, 10184-10189 (2010).
51. Lee, C. L. et al. Generation of primary tumors with Flp recombinase in FRTflanked p53 mice. Dis. Model Mech. 5, 397-402 (2012).
52. Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29, 418-425 (2001).
53. DuPage, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4, 1064-1072 (2009).